HEALTH● LOWJul 16 · Jul 16, 2026, 10:48 AM
Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
CNBC
The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH6m agoKenya: 20 Ebola contacts released from quarantineUN NewsHEALTH36m agoMarijuana and violence: How much more evidence do we need of the connection?The HillHEALTHBREAKING51m agoDR Congo reports over 10,000 Ebola cases as the outbreak spreads abroad, with no approved vaccine or specific treatment for the Bundibugyo virusDW News [en]HEALTH1h agoA 'canary in the coal mine': Measles resurgence exposes weaknesses in U.S. public health, experts sayCNBC